Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer

Şükrü Tüzmen, Galen Hostetter, Aprill Watanabe, Cumhur Ekmekçi, Patricia E. Carrigan, Ishaiahu Shechter, Olli Kallioniemi, Laurence J Miller, Spyro Mousses

Research output: Contribution to journalArticle

Abstract

Aim: To help characterize the FDFT1 gene and protein expression in cancer. Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)51-65
Number of pages15
JournalPersonalized Medicine
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Transferases
Neoplasms
Cholesterol
Enzymes
Metabolic Networks and Pathways
Disease Progression
farnesyl pyrophosphate
Cell Survival
Carcinogenesis
Proteins
Biomarkers
Lipids
Gene Expression
Messenger RNA
Growth

Keywords

  • cancer
  • cholesterol
  • FDFT1
  • gene expression
  • immunohistochemistry
  • lipidrafts
  • microdomains
  • plasma membrane
  • qPCR
  • TMA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Tüzmen, Ş., Hostetter, G., Watanabe, A., Ekmekçi, C., Carrigan, P. E., Shechter, I., ... Mousses, S. (2019). Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer. Personalized Medicine, 16(1), 51-65. https://doi.org/10.2217/pme-2016-0058

Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer. / Tüzmen, Şükrü; Hostetter, Galen; Watanabe, Aprill; Ekmekçi, Cumhur; Carrigan, Patricia E.; Shechter, Ishaiahu; Kallioniemi, Olli; Miller, Laurence J; Mousses, Spyro.

In: Personalized Medicine, Vol. 16, No. 1, 01.01.2019, p. 51-65.

Research output: Contribution to journalArticle

Tüzmen, Ş, Hostetter, G, Watanabe, A, Ekmekçi, C, Carrigan, PE, Shechter, I, Kallioniemi, O, Miller, LJ & Mousses, S 2019, 'Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer', Personalized Medicine, vol. 16, no. 1, pp. 51-65. https://doi.org/10.2217/pme-2016-0058
Tüzmen Ş, Hostetter G, Watanabe A, Ekmekçi C, Carrigan PE, Shechter I et al. Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer. Personalized Medicine. 2019 Jan 1;16(1):51-65. https://doi.org/10.2217/pme-2016-0058
Tüzmen, Şükrü ; Hostetter, Galen ; Watanabe, Aprill ; Ekmekçi, Cumhur ; Carrigan, Patricia E. ; Shechter, Ishaiahu ; Kallioniemi, Olli ; Miller, Laurence J ; Mousses, Spyro. / Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer. In: Personalized Medicine. 2019 ; Vol. 16, No. 1. pp. 51-65.
@article{26666fb390404a3c952176e8c0f7e214,
title = "Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer",
abstract = "Aim: To help characterize the FDFT1 gene and protein expression in cancer. Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.",
keywords = "cancer, cholesterol, FDFT1, gene expression, immunohistochemistry, lipidrafts, microdomains, plasma membrane, qPCR, TMA",
author = "Ş{\"u}kr{\"u} T{\"u}zmen and Galen Hostetter and Aprill Watanabe and Cumhur Ekmek{\cc}i and Carrigan, {Patricia E.} and Ishaiahu Shechter and Olli Kallioniemi and Miller, {Laurence J} and Spyro Mousses",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/pme-2016-0058",
language = "English (US)",
volume = "16",
pages = "51--65",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Characterization of farnesyl diphosphate farnesyl transferase 1 expression in cancer

AU - Tüzmen, Şükrü

AU - Hostetter, Galen

AU - Watanabe, Aprill

AU - Ekmekçi, Cumhur

AU - Carrigan, Patricia E.

AU - Shechter, Ishaiahu

AU - Kallioniemi, Olli

AU - Miller, Laurence J

AU - Mousses, Spyro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: To help characterize the FDFT1 gene and protein expression in cancer. Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.

AB - Aim: To help characterize the FDFT1 gene and protein expression in cancer. Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.

KW - cancer

KW - cholesterol

KW - FDFT1

KW - gene expression

KW - immunohistochemistry

KW - lipidrafts

KW - microdomains

KW - plasma membrane

KW - qPCR

KW - TMA

UR - http://www.scopus.com/inward/record.url?scp=85058745457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058745457&partnerID=8YFLogxK

U2 - 10.2217/pme-2016-0058

DO - 10.2217/pme-2016-0058

M3 - Article

C2 - 30468409

AN - SCOPUS:85058745457

VL - 16

SP - 51

EP - 65

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 1

ER -